Pharmamarketeer

Allecra Therapeutics announces positive results from phase 3 ALLIUM trial of Exblifepfor to treat complicated urinary tract infections

Phase 3

Allecra Therapeutics, a clinical─stage biopharmaceutical company, announced that its investigational product Exblifep (cefepime─enmetazobactam) met the US Food and Drug Administration (FDA) and European Medicines Agency

Medhc-fases-banner
Advertentie(s)